Ethosuximide (Zarontin)
Order Name
ETHOSUXIM
Test Number: 4002550
Revision Date 12/12/2022
Test Number: 4002550
Revision Date 12/12/2022
| Test Name | Methodology | LOINC Code |
|---|---|---|
|
Ethosuximide (Zarontin)
|
Immunoassay (IA) | 3616-0 |
| SPECIMEN REQUIREMENTS | ||||
|---|---|---|---|---|
| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
| Preferred | 1 mL (0.5) | Serum | Clot Activator (Red Top, No-Gel) | Room Temperature |
| Alternate 1 | 1 mL (0.5) | Plasma | EDTA (Lavender Top) | Room Temperature |
| Instructions | Notes: 0.6 mL (Note: This volume Does NOT allow for repeat testing). Specimen Type: Red-top tube, lavender top (EDTA ) tube OR green-top (heparin) tube. DO NOT USE A GEL-BARRIER TUBE. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant. Specimen Storage: Room Temperature Specimen Collection: Transfer separated serum or plasma to a plastic transport tube. Oral: peak: two to four hours after dose; trough: immediately prior to next dose. Peak or trough levels may be used to monitor therapy because blood levels are fairly constant. Special Instructions: State other drugs taken by patient. Specimen Stability: Ambient: 14 days, Refrigerated : 14 days, Frozen: 14 days |
|||
| GENERAL INFORMATION | |
|---|---|
| Expected TAT | 1 - 3 days |
| Clinical Use | Ethosuximide is an anticonvulsant used to treat patients with petit mal, myoclonic, and akinetic seizures. Therapeutic drug monitoring is useful to optimize dose and avoid toxicity. |
| Performing Labcorp Test Code | 007443 |
| Notes | Labcorp Test Code: 007443 |
| CPT Code(s) | 80168 |
| Lab Section | Reference Lab |